

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Meihao Medical Group Co., Ltd

美皓醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1947)

PROFIT WARNING

This announcement is made by Meihao Medical Group Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the information currently available to the Board and a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2023 (the “**Relevant Period**”), it is expected that the Group would record a net loss ranging from approximately RMB1.8 million to approximately RMB2.3 million (for the six months ended 30 June 2022: net profit of RMB10.9 million).

The expected loss was mainly attributed to overall decrease of gross profit due to the following reasons:

- (i) number of visits decreased as a result of the increased number of infections due to the complete lifting of Covid-19 pandemic prevention measures and general downturn in consumer market;
- (ii) a decrease of revenue generated from implant dentistry as a result of the fact that patients are postponing implanting given the implementation of collective procurement dental implants policy (種植牙集採政策), since March 2023; and
- (iii) the fact that the Group is still committed to social responsibilities and maintained the existing number of employees and had no downsizing during the Relevant Period despite of the abovementioned.

Regardless of the current situation, the Group still manages to keep a healthy financial position. The Board will continue to assess the effect of a challenging economic condition on the Group's operation and financial performance, and negotiate with the Group's business partners to discuss if there are any measures can be implemented to improve the Group's financial performance.

At the date of this announcement, the Group is still in the process of finalising its interim results for the Relevant Period. The information contained in this announcement is only based on the preliminary assessment by the Board based on the information currently available and the unaudited consolidated financial information of the Group, which has not been confirmed or reviewed by the auditor of the Company, nor reviewed by the Audit Committee of the Company. Therefore, the above information may be subject to adjustment, and may differ from the information contained in the interim results for the Relevant Period of the Group. The relevant information of the Group's performance for the Relevant Period will be disclosed in the interim results announcement to be issued by the end of August 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Meihao Medical Group Co., Ltd

Mr. Wang Xiaomin

Chairman, Chief Executive Officer and Executive Director

Wenzhou, 11 August 2023

As at the date of this announcement, the Board of the Company includes the executive Directors Mr. Wang Xiaomin and Ms. Zheng Man; and the independent non-executive Directors Mr. Ng Ming Chee, Ms. Tam Hon Shan Celia and Dr. Zhou Jian.